Technologies for measuring HIV-1 drug resistance

HIV Clinical Trials

Volumn 3, Issue 3, 2002, Pages 227-236

  Schmidt, Barbara ^a   Korn, Klaus ^a   Walter, Hauke ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Antiretroviral therapy; Drug resistance; Genotype; Human immunodeficiency virus; Phenotype

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACCURACY; ASSAY; BIOINFORMATICS; CONTROLLED STUDY; DATA BASE; DEVICE; DRUG RESPONSE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; MEASUREMENT; MEDICAL TECHNOLOGY; PHENOTYPE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RELIABILITY; REVIEW;

EID: 0036306169     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/76W8-K4K7-M4KW-W57K     Document Type: Review

References (64)

1. Changing patterns of mortality across Europe in patients infected with HIV-1
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
3. Managing resistance to anti-HIV drugs: An important consideration for effective disease management
4. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
5. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
6. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS
7. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: Week 48 follow-up
8. Phenotypic resistance testing significantly improves response to therapy: Final analysis of a randomized trial (VIRA 3001)
9. A prospective, randomized study on the usefulness of genotypic resistance testing and the assessment of patient-reported adherence in unselected patients failing potent HIV therapy (ARGENTA): Final 6-month results
10. Utility of HIV genotyping and clinical expert advice - The Havana trial
11. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
12. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting
13. Principles of HIV resistance testing and overview of assay performance characteristics
14. Mutations in retroviral genes associated with drug resistance: 2000-2001 update
15. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
16. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
17. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
18. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
19. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors
20. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system
21. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
22. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus
23. Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy
24. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma
25. A novel high-throughput fluorescence-based read-out for detecting phenotypic HIV-1 protease resistance
26. Phenotypic and genotypic resistance assays: Methodology, reliability, and interpretations
27. Biologically relevant cut-off values for phenotypic HIV-1 drug susceptibility testing based on the variation in drug susceptibility in untreated individuals
28. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral treatment
29. Determination of a clinically relevant phenotypic resistance "cutoff" for abacavir using the PhenoSense assay
30. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: A randomized trial (NARVAL, ANRS 088)
31. CCTG 575: A randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy
32. Comparison of HIV-1 drug susceptibility (phenotype) results reported by three major laboratories
33. Subtle changes in susceptibility to d4T predict virologic response to d4T monotherapy after AZT treatment
34. Evaluating HIV-1 coreceptor usage and inhibitors of virus entry using recombinant virus assays
35. Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line
36. + cell clone 1-10 (MAGIC-5)
37. Detection of newly emerging primary genotypic mutations at less than 50 copies/ml with maintained presence at breakthrough in longitudinal plasma samples from patients on triple combination therapy
38. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine
39. Performance of the new ViroSeq HIV-1 genotyping system (version 2) with group M subtype panel and with subtype B clinical research samples at test sites
40. Accuracy of sequencing using a kit-based HIV-1 genotyping assay compared to the Agence Nationale de Recherche sur le SIDA consensus genotyping technique
41. A study on HIV-1 genotyping proficiency in 125 laboratories, using the ENVA-3 panel
42. INNO-LiPA can detect HIV-1 mutants at levels of 4% or less of the total viral population
43. External performance of the INNO-LiPA HIV protease assay for the identification of HIV resistance-associated key mutations to protease inhibitors
44. INNO-LiPA HIV non-nucleosides: An easy assay to identify mutations at codon 103, 106 and 181 of the HIV reverse transcriptase
45. An INNO-LiPA HIV test to identify mutations at codon 151 of the HIV reverse transcriptase
46. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries
47. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
48. A mutation in HIV-1 reverse transcriptase at codon 318 (Y-F) confers high-level non-nucleoside reverse transcriptase inhibitor resistance in clinical samples
49. Analysis of the world-wide evaluation study on HIV-1 genotype interpretation; ENVA-3
50. A quality control trial for HIV-1 drug resistance testing using clinical samples
51. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up
52. Potential mechanism of sustained antiretroviral efficacy of AZT-3TC combination therapy
53. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir
54. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
55. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: The virtual phenotype (Virtual Phenotype)
56. Virtual phenotype is predictive of treatment failure in treatment-experienced patients
57. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333
58. Geno2pheno: A new machine learning approach to predicting phenotypic drug resistance from genotype
59. The application of neural networks in predicting phenotypic resistance from genotypes for HIV-1 protease inhibitors
60. Use of neural networks to define the genetic basis of HIV-1 resistance to d4T
61. A 28 mutation neuronal network model that accurately predicts phenotypic resistance to lopinavir
62. Resistance assay interpretation systems vary widely in method and approach
63. Prediction of virological and immunological outcomes by different interpretation systems for genotypic resistance in a cohort of highly active antiretroviral therapy-failed patients
64. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients